3 Biotech Stocks With Major Catalysts Incoming
Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc. (NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences, Inc. (NASDAQ: GILD) is already one of the most profitable companies on the planet, but a readout expected in the near future could be a big step toward addressing one of the largest unmet needs in medicine. Here's a rundown of upcoming events that will alter perceptions of their candidates' potential in the days and weeks ahead.
Citing a lack of efficacy data, the U.S. Food and Drug Administration initially refused to file PTC Therapeutics Inc.'s application for Duchenne muscular dystrophy (DMD) drug Translarna, but the company knocked the dust off an old rule book and essentially forced the agency to review the submission. European regulators have been more accommodating and currently allow the company to market the drug, under the condition it succeeds in a post-marketing study currently underway.
Image source: Getty Images.
Source: Fool.com
Sarepta Therapeutics Aktie
Bei der Aktie stehen derzeit 0 Sell-Einschätzungen 1 Buy-Einschätzungen gegenüber. Ein echtes Sentiment ist noch nicht auszumachen.
Das Kursziel von 130 € für Sarepta Therapeutics weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 112.65 € hin.
